Institute for Systems Biology Moscow to Present Research Results in HCV therapeutic area at ACoP7 Conference

events
Conference
October 22, 2016

Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.

Oleg Demin Jr, Senior Modeler at Institute for Systems Biology Moscow will present two posters on application of QSP modelling in HCV therapeutic area.

Poster entitled "Prediction of Treatment Efficacy of Direct Antiviral Agent Combinations in Chronic Hepatitis C Patients Using Quantitative Systems Pharmacology Modeling Approach" on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster will demonstrate predictions of results of ongoing clinical trials of direct antiviral agents combinations for chronic hepatitis C patients with genotype 1. QSP model predicts primary endpoint SVR12 quantifying percent of patients with undetectable hepatitis C virus during 12 weeks after treatment completion. Poster ID is M45.

Poster entitled “Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach" on Tuesday, October 25th, 2016 at 7:30am to 9:00am. The poster will demonstrate how QSP model can describe suppression of immune response by hepatitis C virus. The model was applied to predict and explore results of treatment of chronic hepatits C patients with PD-1 inhibitor nivolumab. Poster ID is T56.

About Institute for Systems Biology Moscow (ISBM):

Institute for Systems Biology Moscow, Ltd. (www.insysbio.ru) is a leading R&D company providing services for mathematical modeling in drug research and development. ISBM is one of the pioneers in quantitative system pharmacology (QSP) modeling and simulation services and has been working on the market for more than 10 years. The company’s aim is to assist right decisions on the critical stages of drug research and development. ISBM team continuously improves methods and tools for biological modeling. Moreover, company works with students and postgraduates forming professional community of QSP-modelers. Company has published a lot of scientific studies, and has presented at major international conferences of the field. The ISBM innovative approach has become an integral part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharma industry.

Media contact:
Maria Maximova, media@insysbio.ru

June 2024
MoTuWeThFrSaSu
     
1
2
3
4
5
6
7
8
9
10
11
1. 11 Jun 2024 18:28 InSysBio to participate in JuliaCon2024 InSysBio announces its participation in JuliaCon2024 which is to be held from July 9-13, 2024, at the Philips Stadion, Eindhoven, the Netherlands. Ivan Borisov, Senior Software Developer at InSysBio, will give a lightning talk "Profile Likelihood-based Practical Identifiability in Julia". Moreover, InSysBio team is going to present 2 posters in frames of the Conference
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Upcoming Events
25.06
InSysBio to hold a workshop on IRT at PAGE 2024
26.06
InSysBio to take part in PAGE 2024
09.07
InSysBio to participate in JuliaCon2024
Tags
Latest News
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator
06.04
InSysBio to release Immune Response Template 3.6.2 for QSP modeling
16.01
InSysBio team to publish the new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study”